S886 Chronic Nonsteroidal Anti-Inflammatory Drug Use and Its Association With Microscopic Colitis and Inflammatory Bowel Disease: A Retrospective Case Control Study

Background. The aim of our study was to investigate whether serum cholinesterase (ChE) levels were associated with inflammatory bowel disease (IBD). Materials and Methods. We conducted a retrospective case-control study to clarify the relationship between serum ChE levels and IBD that included 142 patients with ulcerative colitis (UC), 60 patients with Crohn’s disease (CD), and 264 healthy controls (HCs). We used ROC curves to evaluate the diagnostic value of serum ChE levels for IBD. Results. Substantially lower serum ChE levels were detected in patients with UC than in HCs (6376 U/L versus 8418 U/L, P<0.001) and in patients with CD than in HCs (5181 U/L versus 8418 U/L, P<0.001). Additionally, patients with CD displayed significantly lower serum ChE levels than patients with UC (5181 U/L versus 6376 U/L, P<0.01). We also found that there was a negative association between serum ChE levels and the Crohn’s Disease Activity Index (CDAI) score of patients with CD (P=0.011) and the Simple Clinical Colitis Activity Index (SCCAI) score of patients with UC (P=0.018). The area under the curve (AUC) for serum ChE for the diagnosis of IBD was 0.826, and the AUCs of serum ChE for the diagnosis of CD and UC were 0.890 and 0.800, respectively. Conclusions. Serum ChE levels have important clinical significance in the diagnosis and assessment of clinical activity in patients with IBD, and the cholinergic anti-inflammatory pathway may provide new ideas for targeted treatment of IBD.

Download Full-text

Asthma and Inflammatory Bowel Disease: A Population-Based Retrospective Case-Control Study.

10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2181 ◽

2009 ◽

Author(s):

Y Fenta ◽

N Tello ◽

J Jung ◽

B Li ◽

EV Loftus ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Case Control Study ◽

Population Based ◽

Case Control ◽

Retrospective Case ◽

Inflammatory Bowel ◽

Control Study

Download Full-text

P-043 The Risk of Ectopic Pregnancy in Patients with Inflammatory Bowel Disease—A Retrospective Case Control Study

Inflammatory Bowel Diseases ◽

10.1097/01.mib.0000438684.01038.c0 ◽

2013 ◽

Vol 19 ◽

pp. S42

Author(s):

Punyanganie de Silva ◽

Ashwin Ananthakrishnan ◽

Sonia Friedman

Keyword(s):

Inflammatory Bowel Disease ◽

Ectopic Pregnancy ◽

Bowel Disease ◽

Case Control Study ◽

Case Control ◽

Retrospective Case ◽

Inflammatory Bowel ◽

Control Study

Download Full-text

Risk Factors for Developing Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Retrospective Case–Control Study

Journal of the Canadian Association of Gastroenterology ◽

10.1093/jcag/gwaa024 ◽

2020 ◽

Author(s):

Parul Tandon ◽

Vivek Govardhanam ◽

Zane Gallinger ◽

Adam V Weizman

Keyword(s):

Risk Factors ◽

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Hidradenitis Suppurativa ◽

Case Control Study ◽

Case Control ◽

Perianal Disease ◽

Retrospective Case ◽

Inflammatory Bowel ◽

Control Study

Abstract Background Hidradenitis suppurativa (HS) is associated with inflammatory bowel disease (IBD), though risk factors remain to be determined. Aim To characterize HS among a cohort of IBD patients and identify risk factors for its development. Methods This was a retrospective case–control study at the ambulatory IBD centre at Mount Sinai Hospital from inception to May 2019. Patients with IBD who developed HS were included. Cases were matched 5:1 by age, gender (male versus female) and IBD type (ulcerative colitis [UC] or Crohn’s disease [CD]) to controls who had IBD without HS. Conditional logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (95% CIs). Results Twenty-nine cases of HS (19 CD and 10 UC) and 145 controls were included. Of the 29 patients with HS, 11 (37.9%) were male and 18 (62.1%) were female. The severity of HS was mild in 10 (34.5%), moderate in 16 (55.2%) and severe in 3 (10.3%) patients. Patients with HS and IBD were more likely to be active (OR 10.3, 95% CI 2.0 to 54.0, P = 0.006) or past (OR 8.4, 95% CI 2.7 to 25.8, P < 0.005) smokers. Patients with HS and IBD were also more likely to have active endoscopic disease (OR 3.8, 95% CI 1.2 to 12.2, P = 0.022). Furthermore, those with HS and CD were more likely to have active perianal disease (OR 21.1, 95% CI 6.2 to 71.9, P < 0.005). Conclusions Active IBD, perianal disease and smoking may be associated with HS in IBD. Larger studies are needed to better characterize this morbid condition.

Download Full-text

Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease—A Single Center Case–Control Study

Journal of Clinical Medicine ◽

10.3390/jcm10143177 ◽

2021 ◽

Vol 10 (14) ◽

pp. 3177

Author(s):

Edyta Szymanska ◽

Maciej Dadalski ◽

Joanna Sieczkowska-Golub ◽

Dorota Jarzebicka ◽

Monika Meglicka ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Pediatric Patients ◽

Case Control Study ◽

Case Control ◽

Chi Square ◽

Infusion Reactions ◽

Inflammatory Bowel ◽

The Difference ◽

Control Study

Background: Infusion reactions (IRs) are the most common adverse events (AEs) of infliximab (IFX) treatment in patients with inflammatory bowel disease (IBD). Prophylactic premedication (PM) with corticosteroids or antihistamines prior to IFX infusions has been used in clinical practice, but its efficacy is not known. The aim of this study was to assess the influence of steroid PM on IR incidence in pediatric patients with IBD receiving IFX. Methods: We performed a case–control study that included pediatric patients with IBD receiving IFX. Patients were divided into four subgroups according to the agent and PM they received: Remicade (original drug) + PM, and two biosimilars—Reshma +/− PM, and Flixabi—PM. At our site, until 2018, PM with steroids was used as a part of standard IFX infusion (PM+); however, since then, this method has no longer been administered (PM−). IRs were divided into mild/severe reactions. Differences between subgroups were assessed with the appropriate chi-square test. Multivariate logistic regression was used to assess associations between PM and IR incidence, correcting for co-medication usage. Results: There were 105 children (55 PM+, 44 male, mean age 15 years) included in the study who received 1276 infusions. There was no difference between the PM+ and PM− subgroups, either in incidence of IR (18.2% vs. 16.0% of patients, p > 0.05) or in percentage of infusions followed by IR (2.02% vs. 1.02% of infusions, p > 0.5). The OR of developing IR when using PM was 0.34, and the difference in IRs ratio in PM+ and PM− patients was not statistically significant (95% CI, 0.034–1.9). There were 11/18 (61.1%) severe IRs (anaphylactic shock) reported in all patients (both PM+ and PM−). Conclusion: At our site, the incidence of IR was low, and PM did not decrease the incidence of IR in pediatric patients with IBD receiving IFX. These results indicate that PM with steroids should not be a standard part of IFX infusion to prevent IR.

Download Full-text